TargImmune Therapeutics AG is a private Swiss-based biotechnology company developing a novel targeted cancer treatment modality. TargImmune has a unique dsRNA non-viral vector delivery platform which, by mimicking a virus, harnesses the body's powerful antiviral defenses to address cancer tumors including distant metastases. The targeted nanoparticles drive a combination of apoptosis (cell death) and modulation of the innate and adaptive immune cells to target both primary and metastatic heterogeneous tumour cells. TargImmune’s therapeutics are the first in a new class known as Targeted Apoptotic Immune Modulators (TAIMs). TargImmune’s unique viral mimicry approach is fundamentally different to any of the other classes of anticancer agents in the clinic and has the potential to transform outcomes for cancer patients.